glp 1 agonist lilly Lilly's Easy-to Use Once-Weekly GLP-1 Trulicity Approved in Europe Lilly's oral GLP-1, orforglipron, superior

Unlike older compounds in its class, it specifically targets the growth hormone secretagogue receptor without significantly elevating cortisol, prolactin, or ACTH levels during assays

Ozempic (semaglutide) has dominated the GLP-1 market due to its early approval, strong efficacy in glycemic control, and weekly administration convenience

The availability of oral formulations addresses patient preferences for non-injectable medications while the entry of additional manufacturers beyond the current duopoly is expected to improve supply availability and create pricing competition that will facilitate broader access

Accuracy of Surrogate Matrix Fortified plasma samples were prepared from three different lots of plasma and analyzed using calibrators prepared in BSA to test the accuracy of using BSA as a surrogate matrix for underivatized acylcarnitines analysis

WHO (2025)